Redunera IP Declaration

Date: June 30, 2025

To Whom It May Concern,

This letter formally affirms that the therapeutic blueprint known as \*\*Redunera\*\* was developed

independently by Kunfirm Technologies using proprietary SEI-quided Moleculogic Tier 4 design systems.

Redunera is not derived from any third-party investigational or approved compound. While it addresses a

similar clinical challenge-preserving kidney function and mitigating inflammation in CKD patients with

comorbid hypertension or type 2 diabetes-it does so through an entirely novel logic framework and

composition.

Key distinctions include:

- SEI-constructed therapeutic logic layers

Original logic-gated delivery system (ROS/pH-responsive)

- Unique entropy stabilization strategies

- Independent targeting mechanisms (renal-specific ligands)

- Non-derivative feedback modulation (immune and redox)

Kunfirm Technologies holds full ownership over the Redunera blueprint, simulation outputs, and all

associated files under SEI Moleculogic logic governance. Any commercial use, data reference, simulation

application, or distribution of Redunera must be explicitly licensed from Kunfirm Technologies.

This declaration serves as an assertion of sovereignty, IP independence, and readiness for registration or

Page 1

## **Redunera IP Declaration**

enforcement as required.
Respectfully,
Kunfirm Technologies
SEI   Moleculogic Division
Email: kunfirm@metaldrug.com